Waters (Waters) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is Waters Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Waters is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Waters's Risk Assessment

For the Diagnostics & Research subindustry, Waters's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Waters's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Waters's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Waters's Risk Assessment falls into.

Waters (NYSE:WAT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Waters Risk Assessment Related Terms

Thank you for viewing the detailed overview of Waters's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Waters (Waters) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Waters Corp (NYSE:WAT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

WAT:Mexico WAZ:Germany

Address

34 Maple Street, Milford, MA, USA, 01757

Website

https://www.waters.com

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.

Executives

Christopher A Kuebler	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Richard H Fearon	director	1239 GERBING ROAD, AMELIA ISLAND FL 32034
Edward Conard	director
Daniel J. Brennan	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Mark P Vergnano	director	1007 MARKET STREET, WILMINGTON DE 19898
Gary E Hendrickson	director	1101 THIRD STREET SOUTH, MINNEAPOLIS MN 55415
John M Ballbach	director
Linda Baddour	director	PRA INTERNATIONAL, 12120 SUNSET HILLS ROAD, SUITE 600, RESTON VA 20190
Michael J Berendt	director
Thomas P Salice	director
Wei Jiang	director	34 MAPLE STREET, MILFORD MA 01757
Amol Chaubal	officer: SVP and Chief Financial Office	113 HARTWELL AVE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421
Jianqing Bennett	officer: SVP TA Instruments Division	34 MAPLE STREET, MILFORD MA 01757
Joann A Reed	director	C/O AMERICAN TOWER CORP, 116 HUNTINGTON AVENUE, BOSTON MA 02116
Belinda Hyde	officer: SVP, Global Human Resources	13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277